PT-141
$21.99 – $39.99Price range: $21.99 through $39.99
An FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
Molecular & analytical data
Verified chemistry and third-party reference identifiers for this compound.

Reconstitution calculator
Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →
—
A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.
Quality & verification
Every batch is characterised before release and ships with documentation.
Storage & handling
Keep the peptide stable from delivery through reconstitution.
Refrigerate at 2-8°C. Protect from light.
PT-141, marketed as Bremelanotide (Vyleesi), is a synthetic melanocortin receptor agonist that enhances sexual desire through central nervous system pathways rather than vascular mechanisms (unlike PDE5 inhibitors like Viagra). It non-selectively activates melanocortin receptors, particularly MC1R and MC4R, in brain regions involved in sexual arousal. FDA-approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). PT-141 was originally derived from Melanotan II research and represents one of the few approved treatments for female sexual dysfunction.
Certificates of Analysis
Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.
| Batch # | Issued | Purity | Certificate |
|---|---|---|---|
| NHV26-K8856 COA-G4ZZ-JT0P-R | 04 Aug 2026 | 98.87 % HPLC | Verify at IRZC ↗ |
“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.
The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.
Mechanism of action
Non-selective melanocortin receptor agonist (primarily MC1R and MC4R), activates sexual arousal pathways in CNS, enhances dopaminergic signaling related to desire, does not act on vascular system (non-vasodilatory).
Primary uses / indications
Hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA-approved), sexual dysfunction research, libido enhancement
Typical dosage (reported)
1.75 mg subcutaneous injection, at least 45 minutes before anticipated sexual activity. Maximum 1 dose per 24 hours, max 8 doses per month.
Cycle duration (reported)
As-needed basis; not for daily use
Administration route
Subcutaneous injection (auto-injector)
Side effects (reported)
Nausea (most common, ~40%), flushing, injection site reactions, headache, transient hypertension, skin hyperpigmentation with frequent use, fatigue.
Contraindications
Uncontrolled hypertension, known cardiovascular disease. Not approved for men or postmenopausal women. (Orally administered naltrexone-containing products appear in the Vyleesi label as a drug interaction to avoid, not as a contraindication.)
Drug interactions
Contraindicated with naltrexone. Caution with antihypertensives. May cause transient blood pressure elevation.
Identity
| Full name / brand names | PT-141 (Bremelanotide / Vyleesi) |
|---|---|
| Category | Sexual Health & Hormonal |
| Subcategory | Melanocortin Agonist |
| Origin / source | Synthetic melanocortin peptide; discovered and developed by Palatin Technologies. AMAG Pharmaceuticals held exclusive North American commercialisation rights under a January 2017 licence and marketed Vyleesi; the licence was mutually terminated in July 2020 and all North American rights returned to Palatin. |
| Year discovered | FDA approved 2019 (Vyleesi) |
Chemistry
| Amino acid sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
|---|---|
| Molecular formula | C50H68N14O10 |
| Molecular weight | 1025.17 g/mol |
| CAS number | 189691-06-3 |
| PubChem CID | CID 9941379 ↗ |
| Purity standard | ≥98% |
Pharmacokinetics
| Half-life | ~2.7 hours (range 1.9-4.0 hours) |
|---|---|
| Bioavailability | Subcutaneous: ~100% |
Regulatory & research status
| FDA status | FDA-Approved (2019) as Vyleesi for HSDD in premenopausal women. |
|---|---|
| Prescription required | Yes — prescription required |
| Research status | FDA-approved with clinical trial data. Research ongoing for male sexual dysfunction and other melanocortin-mediated conditions. |
| Clinical trials | NCT02333071 (BMT-301) and NCT02338960 (BMT-302), the two phase III bremelanotide HSDD studies; FDA-approved as Vyleesi (2019) |
References
Kingsberg SA et al., "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials", Obstetrics & Gynecology, 2019, DOI: 10.1097/AOG.0000000000003500; Clayton AH et al., "Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial", Women's Health, 2016, DOI: 10.2217/whe-2016-0018
Frequently asked questions
What is PT-141?
How does PT-141 work?
What PT-141 dosage is used in research?
What is the half-life of PT-141?
How should PT-141 be stored and reconstituted?
What purity is NHOV's PT-141?
Is PT-141 approved for human use?
Related products
Melanotan 1
Linear 13-amino-acid alpha-MSH analog; an MC1R-selective melanocortin agonist.
$21.99 – $34.99Price range: $21.99 through $34.99Melanotan II
Non-selective melanocortin receptor agonist studied in melanogenesis research.
$20.99 – $34.99Price range: $20.99 through $34.99Triptorelin
Synthetic decapeptide GnRH agonist; sustained exposure desensitizes the pituitary.
$34.99 – $54.99Price range: $34.99 through $54.99Kisspeptin-10
Neuropeptide acting at KISS1R; studied for GnRH and reproductive axis research.
$34.99 – $45.99Price range: $34.99 through $45.99Oxytocin
Endogenous neuropeptide hormone studied in social behavior and anxiety research.
$33.99 – $49.99Price range: $33.99 through $49.99Gonadorelin
Synthetic gonadotropin-releasing hormone studied in pituitary function research.
$39.99 – $63.99Price range: $39.99 through $63.99
Pre-order 
Thyrotropin TRH
Hypothalamic tripeptide hormone that triggers pituitary TSH and prolactin release.
$34.99 – $54.99Price range: $34.99 through $54.99










Reviews
Clear filtersThere are no reviews yet.